Patients with refractory or relapsed JMML must have had at least one cycle of intensive frontline therapy or at least  cycles of a deoxyribonucleic acid (DNA) demethylating agent with persistence of disease, defined by clinical symptoms or the presence of a clonal abnormality; frontline therapy is defined as one cycle of intravenous chemotherapy that includes of any of the following agents: fludarabine, cytarabine, or any anthracycline but specifically excludes oral -mercaptopurine; frontline therapy will also include any conditioning regimen as part of a stem cell transplant; patients who transform to acute myeloid leukemia (AML) with more than % blasts at relapse are not eligible for this trial
Participants must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; participants with uncontrolled Kaposi sarcoma are permitted (KS must be increasing despite HAART and HIV suppression for greater than or equal to  months, or stable KS despite HAART for greater than or equal to  months)\r\n* For participants in the  participant solid tumor cohort, only those histologies not known to respond to single agent nivolumab (such as pancreas, prostate, and microsatellite stable [MSS] colorectal cancer) will be excluded\r\n* For participants in the relapsed refractory HIV-cHL expansion cohort, participants must have histologically confirmed, relapsed/refractory (defined as relapsed/refractory to one or greater lines of therapy) HIV-associated classical Hodgkin lymphoma
relapsed and refractory multiple myeloma (RRMM): subjects who have received at least  prior regimen, were responsive to at least  prior regimen (as defined by IMWG criteria) and then are refractory to their most recent therapy (? % response or progression during therapy or within  days after completion of therapy). Prior therapies for subjects with PRMM or RRMM must include an immunomodulatory drug (IMiD) and a proteasome inhibitor as separate lines or a combined line of therapy. If prior therapy includes autologous stem cell transplantation (ASCT), then induction/ASCT/maintenance therapies will be considered as one line of therapy altogether. Subjects who have relapsed after ASCT or are unable to receive ASCT are eligible. The interval from ASCT to entry in the study must be ? weeks.
Diagnosis of one of the following:\r\n* Relapsed/refractory peripheral T-cell lymphoma of any subtype including mycosis fungoides and Sezary syndrome of advanced stage (IIB-IVB)\r\n** For the expansion cohort: patients must have biopsy-proven T-cell lymphoma and measurable disease\r\n* Relapsed/refractory DLBCL (up to  DLBCL patients are allowed in the dose-escalation portion of the study)\r\n* Relapsed/refractory Hodgkin lymphoma (HL)\r\n* Note: extracorporeal photopheresis is NOT considered a systemic therapy for this study
PROCUREMENT: Diagnosis of Hodgkins or non-Hodgkins lymphoma:\r\n* GROUP A: \r\n** With active disease \r\n*** In second or subsequent relapse\r\n*** In first relapse for indolent lymphoma after first line therapy for relapse\r\n*** Or first relapse if immunosuppressive chemotherapy contraindicated\r\n*** Primary refractory disease or if persistent disease after first line therapy of relapse\r\n** Or multiply relapsed patients in remission who are at a high risk of relapse or the lymphoma is a second malignancy e.g. a Richter's transformation of chronic lymphocytic leukemia (CLL) after failing frontline therapy OR\r\n* GROUP B:\r\n** After autologous or syngeneic stem cell transplant (SCT) (as adjuvant therapy)
TREATMENT: Diagnosis of Hodgkins or non-Hodgkins lymphoma:\r\n* GROUP A: \r\n** With active disease \r\n*** In second or subsequent relapse\r\n*** In first relapse for indolent lymphoma after first line therapy for relapse\r\n*** Or first relapse if immunosuppressive chemotherapy contraindicated\r\n*** Primary refractory disease or if persistent disease after first line therapy of relapse\r\n** Or multiply relapsed patients in remission who are at a high risk of relapse or the lymphoma is a second malignancy e.g. a Richter's transformation of CLL after failing frontline therapy OR\r\n* GROUP B:\r\n** After autologous or syngeneic SCT (as adjuvant therapy)
For lymphoma patients only: Participants must have received and relapsed after autologous stem cell transplantation (ASCT), or be ineligible for ASCT (including on the basis of refractory disease), or have declined ASCT
In view of the principal investigator (PI) and the primary oncologist, there must be no available alternative curative therapies or subject has declined to pursue alternative therapy; and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, recurred after SCT, or have disease activity that prohibits SCT at the time of enrollment\r\n* Chemotherapy refractory disease in subjects with B-ALL is defined as progression or stable disease after two lines of therapies\r\n* Recurrence of disease after achieving a complete response (CR)\r\n* Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, polymerase chain reaction [PCR], fluorescence in situ hybridization [FISH], or next generation sequencing) require verification of MRD positivity on two occasions at least  weeks apart\r\n* Subjects with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs)\r\n* Subjects with recurrence of isolated central nervous system (CNS) relapse after achieving complete remission (CR); if relapsed with MRD, will require verification of MRD positivity on two occasions at least  weeks apart
Participants with relapsed primary malignancy, or who have been treated for relapse after the alloSCT was performed
ALK+ ALCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included a multiagent chemotherapy regimen including an anthracycline, if not contraindicated, and prior brentuximab; prior crizotinib or other ALK inhibitor therapy, while recommended, is not mandatory; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant
MCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included a multiagent chemotherapy regimen and prior ibrutinib or other BTK inhibitor therapy; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant
BCL+ DLBCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included an anthracycline, if not contraindicated; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant
Key Inclusion Criteria:\n\n        -Any of the following as defined by the WHO,  lymphoid neoplasm classifications and\n        histologically confirmed:\n\n          -  Diffuse large B-cell lymphoma (DLBCL), Not Otherwise Specified (NOS): Germinal center\n             B-cell type (GCB), Activated B-cell type (ABC)\n\n          -  High-grade B-cell lymphoma (HGBCL) NOS\n\n          -  HGBCL with MYC and BCL and/or BCL rearrangements\n\n          -  T-cell histocyte-rich large B-cell lymphoma\n\n          -  EBV+ DLBCL, NOS\n\n          -  HHV+ DLBCL, NOS\n\n        Relapsed or refractory disease following at least  lines (and a maximum of  lines) of\n        prior rituximab containing multi-agent chemotherapy which may include an autologous stem\n        cell transplantation unless patients are not considered suitable for intensive second-line\n        chemotherapy or autologous stem cell transplantation. Patients who are ineligible for\n        intensive second line chemotherapy,must have received at least one prior\n        rituximab-containing combination chemotherapy regimen. Patients who are ineligible for\n        intensive second line chemotherapy, must have received at least one prior\n        rituximab-containing combination chemotherapy regimen.\n\n          -  Baseline measurable disease with at least  bi dimensional lesion with longest\n             diameter (LDi) >.cm on CT scan which is FDG avid on PET scan.\n\n          -  A biopsy (archived or Screening/recent) will be collected at Screening.\n\n          -  At least years of age (or ? years in Japan).\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)  or .\n\n        Key Exclusion Criteria:\n\n          -  Active central nervous system (CNS) lymphoma.\n\n          -  Prior organ transplantation including prior allogeneic SCT.\n\n          -  Prior therapy with an anti PD , anti PD L, anti PD L, anti CD, or anti cytotoxic\n             T lymphocyte associated antigen  (CTLA ) antibody (including ipilimumab,\n             tremelimumab or any other antibody, or drug specifically targeting T cell co\n             stimulatory or immune checkpoint pathways).
Adult subjects with advanced MDS or CMML requiring therapy who were previously treated with either azacitidine or decitabine for at least  cycles and deemed to have failed therapy due to progression of disease using International Working Group (IWG) criteria (refractory) or losing their previously documented response to the therapy (relapsed) and who are ineligible for allogeneic stem cell transplant
Failed at least one trial of immunosuppressive therapy (IST) by being refractory or having relapsed. IST could have included ATG based regimens, calcineurin inhibitors and/or other higher dose therapy directed at the treatment of primary SAA.
Refractory (no prior CR/CMR) or relapsed (prior CMR) following front line treatment of standard multiagent chemotherapy containing an anthracycline AND an approved anti-CD agent. For subjects with refractory disease and who have received radiotherapy, PET positivity should be demonstrated no less than  weeks after the last dose of radiotherapy
Patients with relapsed or refractory classical HL who have previously received autologous stem cell transplant (ASCT); patients must have received prior ASCT at least  weeks ( months) before the first dose of ibrutinib or patients with relapsed or refractory HL who have failed at least  lines of prior therapy and are not eligible for ASCT due to:\r\n* Inability to achieve a complete response (CR) or partial response (PR) prior to transplant\r\n* Age or comorbid conditions\r\n* Inability to collect stem cells
Histologically-confirmed relapsed or refractory CD+ B-cell lymphoma of one of the following types, with documented disease progression or recurrence following the immediate prior therapy:
For subjects with DLBCL, PMBCL, and Grb-FL: relapsed or refractory disease following at least  prior regimens or following an auto-HSCT
For subjects with TH-FL: relapsed or refractory disease following at least  prior regimens or following an auto-HSCT. At least  prior regimen with an anti-CD mAb in combination with chemotherapy is required following documented transformation
Pathology confirmed relapsed or refractory T-cell lymphoma (PTCL and stage > IB CTCL) at treating institution
Patients must have histologically confirmed relapsed or refractory non-Hodgkins lymphoma or Hodgkins lymphoma (World Health Organization [WHO] criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant; patients may have relapsed after prior stem cell transplant
Disease must be refractory to conventional induction therapy or relapsed after initial standard therapy for ALL; any number of prior therapies is permitted and including allogeneic and/or autologous stem cell transplant
Patients with histological confirmation of relapsed/refractory non-GCB type (using Hans algorithm) diffuse large B cell lymphoma (DLBCL) or relapsed/refractory primary CNS lymphoma (PCNSL) with at least one of the following characteristics:\r\n* Definition of refractory disease: progression of disease based on Cheson criteria for DLBCL or international primary CNS lymphoma cooperative group for PCNSL either with nonresponse or progression within  months of prior therapy\r\n* Definition of relapsed disease: progression of disease based on Cheson criteria for DLBCL or International primary CNS lymphoma cooperative group for PCNSL at least  months after prior therapy\r\n* Definition of non-GCB subtype (Hans algorithm): cases will be subclassified based on immunohistochemical staining with CD, BCL- and MUM- as previously described.\r\n* Patients should have exhausted (or be ineligible for) approved therapies known to provide clinical benefit for DLBCL or PCNSL (e.g. high dose chemotherapy with autologous stem cell transplant, chimeric antigen receptor-transduced [CAR-T] therapy, etc.).
Participants must have a diagnosis of acute lymphoblastic leukemia and disease meets at least one of the following criteria:\r\n* Relapsed or refractory to chemotherapy as defined by ? % leukemic blasts in the bone marrow\r\n* Relapsed after hematopoietic stem cell transplantation (HSCT)
Osteosarcoma cohort only: Subjects with osteosarcomas must have relapsed or become refractory to conventional therapy and have received a regimen including some combination of high-dose methotrexate, doxorubicin, cisplatin, and/or ifosfamide.
Subjects must have relapsed/refractory DLBCL or relapsed/refractory FL\r\n* For DLBCL, patients must have relapsed after, declined, or considered ineligible for high-dose chemotherapy and autologous stem cell transplantation\r\n* For FL, in addition to relapsed/refractory disease status, patients must have received therapy with CD antibody-directed therapy, and must have an indication for treatment; FL eligibility also requires patients have no standard options with curative potential, nor options with more favorable risk/benefit ratio in the judgment of the investigator
Relapsed or refractory to prior standard therapy and subjects who are not candidates for high-dose therapy or autologous stem cell transplant
Have relapsed or treatment refractory disease with >= % CD+ malignant plasma cells (IHC) on bone marrow (BM) core biopsy, either:\r\n* Following autologous stem cell transplant (ASCT)\r\n* Or, if a patient has not yet undergone ASCT, the individual must:\r\n** Be transplant ineligible, due to age, comorbidity, patient choice, insurance reasons, concerns of rapidly progressive disease, and/or discretion of attending physician, and,\r\n** Demonstrate disease that persists after >  cycles of induction therapy and that is double refractory (persistence/progression) after therapy with both a proteasome inhibitor and immunomodulatory drug (IMiD) administered either in tandem, or in sequence.
Patients must have relapsed (first or greater relapse) or refractory T-cell acute lymphoblastic leukemia (T-ALL) with: \r\n* Relapsed T-ALL with an M (blasts >=  to =< %) or M (> % blasts) marrow with or without an extramedullary site of relapse; including central nervous system (CNS)  OR\r\n* Refractory disease after induction failure of newly diagnosed patients OR no more than two more cycles of therapy OR\r\n* Refractory disease with no more than one prior salvage attempt following the current relapse
Subjects must have received at least one line of systemic therapy in the advanced/metastatic setting. Subjects with diseases without known effective options are also eligible. a) Subjects with relapsed and/or refractory lymphoma must have had at least  prior lines of systemic therapy and are not candidates for high dose therapy/autologous stem cell transplant.
Relapsed/refractory disease, or inadequate response to at least  cycles of hypomethylating therapy. Subjects must not have received any MDS or MAL directed therapy for > days prior to receiving the study treatment.
For B-ALL\r\n* Chemotherapy refractory disease in subjects with B-ALL is defined as progression or stable disease after two lines of lines of therapies\r\n* Recurrence of disease after achieving complete remission (CR)\r\n* Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, polymerase chain reaction [PCR], fluorescence in situ hybridization [FISH], or next generation sequencing) require verification of MRD positivity on two occasions at least  weeks apart\r\n* Subjects with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs)\r\n* Subjects with recurrence of isolated central nervous system (CNS) relapse after achieving complete remission (CR); if relapsed with MRD, will require verification of MRD positivity on two occasions at least  weeks apart
Pathologically confirmed stage IV unresectable relapsed, or unresectable refractory abdominal neuroendocrine tumor from the last biopsy available which may be the initial diagnostic biopsy; relapsed disease is defined as progressive disease following systematic therapy with lanreotide or equivalent and either sunitinib or everolimus or both; refractory disease is defined as disease not responding to or having progressed within  month of the last dose of most recent systemic therapy to include lanreotide or an analog and either sunitinib or everolimus; (Note, small cell carcinoma and large cell undifferentiated neuroendocrine tumors will be excluded from this trial)
Previously treated ASCT naive MM patients, currently with relapsed or refractory disease who are being considered for single ASCT for relapsed disease; patients must be eligible to undergo a stem cell transplant as per institutional criteria for selection at the time of registration
for subjects with DLBCL, PMBCL, and Grb-FL: relapsed or refractory disease following at least  prior regimens or following an auto-HSCT
for subjects with TH-FL: relapsed or refractory disease following at least  prior regimens or following an auto-HSCT. At least  prior regimen with an anti-CD mAb in combination with chemotherapy is required following documented transformation
Diagnosis of R/R B-cell NHL or ALL as defined below:\r\n* Relapsed or refractory B-cell NHL meeting all of the following criteria:\r\n** Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); high grade B cell lymphoma with MYC and BCL and/or BCL rearrangements; LBCL transformed from any indolent histology; or primary mediastinal B-cell lymphoma (PMBCL)\r\n** Prior treatment with an anthracycline and rituximab or another CD-targeted agent (unless the disease is CD-negative); transformed DLBCL (tDLBCL) must have failed treatment for DLBCL\r\n** At least one of the following:\r\n*** Refractory disease after frontline chemo-immunotherapy\r\n*** Not eligible for autologous hematopoietic stem cell transplant (auto-HSCT)\r\n*** Relapsed or refractory disease after at least  lines of therapy or after auto-HSCT\r\n*** Relapsed or refractory disease after allogeneic hematopoietic stem cell transplant (allo-HSCT)\r\n* Relapsed or refractory B-cell ALL (patients with Burkitts lymphoma/leukemia are not eligible)\r\n* All B-ALL patients must have detectable disease by morphology, flow cytometry, cytogenetic analysis (e.g. polymerase chain reaction [PCR], fluorescence in situ hybridization [FISH], karyotyping) or imaging (positron emission tomography [PET]-computed tomography [CT])\r\n** Refractory: failure to achieve complete response (CR) (minimal residual disease [MRD]-negative) at the end of induction\r\n** Relapsed: recurrence of disease after achieving CR
Patients with a diagnosis of CD-positive acute lymphoblastic leukemia (ALL) based on local immunophenotyping and histopathology who have:\r\n* Refractory disease, defined as disease progression or no response while receiving their most recent prior anti-cancer therapy,\r\n* Relapsed disease, defined as response to their most recent prior anti-cancer therapy with subsequent relapse
Patients with ALL, CLL, NHL with relapsed disease following standard therapy or a stem cell transplant.
Patients must have disease that has relapsed after or is refractory to at least  lines of standard therapy; the remaining standard treatment options are unlikely to be effective in the opinion of the treating physician, or patient is felt to be ineligible for such therapies or the patient refuses such therapies; patients who have undergone autologous stem cell transplant are eligible as long as they meet all other criteria
Chemotherapy refractory disease in aggressive NHL is defined as\r\n* Stable disease of =<  months or progressive disease as best response to most recent chemotherapy containing regimen\r\n* Disease progression or recurrence =<  months of prior autologous stem cell transplantation (SCT)
Meets one of the following disease criteria:\r\n* Multiple myeloma (MM) meeting one of the following:\r\n** Relapsed/refractory disease after two lines of therapies, including a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) and an immunomodulatory drug (thalidomide, lenalidomide or pomalidomide)\r\n** Relapsed disease between - months of st autologous stem cell transplantation\r\n** Relapsed disease at least  months after allogeneic stem cell transplantation with no evidence of active graft versus host disease AND with measurable disease defined as serum IgG, A, M M-protein >= . g/dL or serum IgD M-protein >= . g/dL, or urine M-protein >=  mg/ hours AND at least at least  weeks since plasmapheresis\r\n* CD-positive B-cell non-Hodgkin lymphoma (NHL)\r\n** CD expression confirmed by flow cytometry or immunohistochemistry and meeting one or more of the following:\r\n** Evidence of relapsed/refractory disease that has failed conventional therapy\r\n** Relapsed disease at least  days after autologous stem cell transplantation\r\n** Relapsed disease at least  months after allogeneic stem cell transplantation with no evidence of active graft versus host disease\r\n** Has measurable disease > . cm in diameter
Relapsed or refractory:\r\n* Multiple myeloma (MM) previously treated with an immunomodulatory drug (IMID), a proteosome inhibitor and an alkylating agent; OR\r\n* Acute myeloid leukemia (AML), excluding acute promyelocytic leukemia (PML-RARA rearranged- AML-M); either primary refractory or relapsed/refractory disease after at least two front line chemotherapy regimens (note: induction and consolidation chemotherapy is considered one line of therapy); diagnosis based on  World Health Organization (WHO) criteria; OR\r\n* Relapsed T-cell lymphoma (TCL) or the following types: peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell (ALCL), and cutaneous TCL (CTCL) of mycosis fungoides (MF); patients should have failed standard therapy and in the case of PTCL-NOS, AITL, and ALCL either have failed or be ineligible for high-dose therapy with autologous stem cell transplant
Patients diagnosed with acute myeloid leukemia (AML) by World Health Organization (WHO) classification, meeting one of following criteria:\r\n* Age  or older, newly diagnosed, untreated, who are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines\r\n* Age  or older with relapsed or refractory disease\r\n* Younger adult patients with previously untreated high-risk disease (complex karyotype, inv[] or t[;], t[;], monosomal karyotype, therapy-related and secondary disease) that are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines and/or allogeneic stem cell transplantation\r\n* Younger patients with refractory/relapsed AML who are otherwise not candidates for allogeneic stem cell transplantation\r\n* Patients with extramedullary disease who meet one of the above criteria may be included
Subjects must have a histologically determined B cell NHL subtype as defined in the bullets below. In addition, they must have disease that is primary refractory after initial therapy or have relapsed disease.
Subjects with acute myeloid leukemia (AML) should have failed any prior induction therapy regimen or have relapsed after prior therapy (defined as patients in first relapse and less than  months from diagnosis [short first remission] or in second or later relapse; refractory defined as failure to achieve complete response [CR] to standard induction therapy, such as \ and \, high dose ara-C-containing regimen or a hypomethylating agent): dose-escalation phase: subjects with confirmed relapsed or refractory AML and no available treatment options with known benefit; expansion phase: subjects with relapsed/refractory AML who have failed therapy with up to one prior salvage regimen and no available treatment options with known benefit; exception: stem cell transplant (SCT) or stem cell therapy for subjects who previously underwent SCT/stem cell therapy, and are currently in remission will not be considered a salvage regimen
Disease status defined as:\r\n* Patients with relapsed or refractory DLBCL that has relapsed post-transplant or that has been determined to be ineligible or unsuitable for transplant; patients must have to have received at least one prior systemic therapy
Patients with relapsed/refractory stage IIB-IV cutaneous T cell lymphoma who have received at least one standard systemic treatment such as extracorporeal photopheresis, bexarotene, or interferon
Relapsed or refractory B-cell ALL:\r\n* st or greater bone marrow (BM) relapse OR\r\n* Any marrow relapse after allogeneic hematopoietic stem cell transplantation (HSCT) and >  days from transplant OR\r\n* For patients with refractory disease:\r\n** <  years old that have not achieved a complete remission (CR) after >  or more chemotherapy regimens\r\n** >=  years old that have not achieved a CR after  prior chemotherapy regimen
For Part  and Part  of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL. Participants will be considered to have a relapsed disease if they showed a duration of response of at least  weeks after their first line of therapy. The following participants with relapsed DLBCL will be enrolled:
Relapsed disease after standard chemotherapy
That is relapsed or refractory after treatment with an approved therapy(ies), defined as metastatic or non-resectable, locally advanced disease that has previously been treated with and progressed following approved therapy(ies) (Cohort )
Hematologic Malignancy\r\n* No human leukocyte antigen (HLA) identical sibling or suitable unrelated donor, or time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant\r\n* Relapsed or primary therapy-refractory acute myeloid leukemia (AML) with bone marrow blast < %\r\n* High-risk refractory or relapsed acute lymphoblastic leukemia (ALL) in patients for whom transplantation is deemed indicated (relapse occurring <  months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after nd remission, primary induction failure or hypodiploidy)\r\n* Patients with relapsed Hodgkin lymphoma unable to achieve nd remission or very good partial remission (VGPR) and therefore ineligible to receive autologous stem cell transplantation\r\n* Patients with Hodgkin lymphoma relapsing after autologous stem cell transplant\r\n* Patients with primary refractory or relapsed non-Hodgkin lymphoma (NHL) unable to achieve nd remission or very good partial remission (VGPR) and therefore ineligible to receive autologous stem cell transplantation\r\n* Patients with NHL relapsing after autologous stem cell transplant\r\n* Patients with myelodysplastic syndrome (MDS)/myeloproliferative syndrome (MPS)
Solid Tumor\r\n* Failed or ineligible to receive autologous transplant or if autologous transplant would not offer > % chance of cure\r\n* Neuroblastoma\r\n** High risk with relapsed or refractory disease\r\n* Soft tissue sarcoma (rhabdomyosarcoma, Ewing sarcoma, primitive neuroectodermal tumor, or other high-risk extracranial solid tumors)\r\n** Relapsed or primary refractory metastatic\r\n** st complete remission, but very high-risk features (i.e., < % survival with conventional therapy)\r\n* Osteosarcoma\r\n** Failure to achieve complete remission (CR) following initial therapy\r\n** Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapy
Patients with recurrent/relapsed AA will be eligible for the trial as long as they were not previously refractory to hATG-based therapy and the relapse occurred >  months after response.
Patients will have a diagnosis of CLL or small lymphocytic lymphoma (SLL), refractory to or relapsed after at least one prior standard therapy or untreated with deletion (del)(p) by fluorescence in-situ hybridization (FISH) (high-risk cytogenetics) and have an indication for treatment by IWCLL  criteria (Cohort ) OR have been on ibrutinib for at least  months with measurable persistent disease (absolute lymphocyte count [ALC] >  K/muL, any lymph node > . cm by computed tomography [CT] scan, or > % lymphocytes on bone marrow aspirate differential) (Cohort ), OR patients will have a diagnosis of RT, refractory to and/or relapsed after at least one prior standard therapy or untreated with del(p) by FISH (high-risk cytogenetics) (Cohort )
Relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)\r\n* st or greater bone marrow (BM) relapse OR\r\n* Any marrow relapse after allogeneic hematopoietic stem cell transplant (HSCT) and >  days from transplant OR\r\n* For patients with refractory disease:\r\n** <  years old that have not achieved a CR after >=  or more chemotherapy regimens\r\n** >=  years old that have not achieved a CR after  prior chemotherapy regimen\r\n** Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they have failed tyrosine kinase inhibitor therapy
Patients must have high-risk NB (including v-myc myelocytomatosis viral related oncogene [MYCN] amplified stage ///S of any age and MYCN-non-amplified stage  in patients greater than  months of age) AND:\r\n* Phase I: Patients must have refractory or relapsed NB, resistant to standard therapy; for NB standard therapy includes intensive induction chemotherapy, followed by a variety of consolidation or salvage therapies, depending on response\r\n* Phase II: Patients must have primary or secondary refractory disease in BM, defined as morphologic evidence of NB in BM and/or abnormal  iodine (I)-MIBG uptake in osteomedullary sites, OR patients are in >= nd CR/VGPR
Any patient, regardless of age or sex, with EBV-positive Hodgkins or non-Hodgkins lymphoma (regardless of histologic subtype), or EBV (associated)-T/NK-lymphoproliferative disease or severe chronic active EBV (CAEBV) and; in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission who have a high risk of relapse) OR any patient with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richters transformation of CLL (Group A); patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant; OR in remission or with minimal residual disease status after autologous or syngeneic SCT (Group B)
Patients must have either () refractory or relapsed high-risk NB (including v-myc myelocytomatosis viral related oncogene [MYCN]-amplified stage //S and MYCN-nonamplified stage  in patients greater than  months of age) resistant to standard therapy, or () refractory or relapsed GD-positive tumor after receiving available life-prolonging therapies\r\n* For NB, standard therapy generally includes - cycles of high dose induction chemotherapy followed by resection of gross residual tumor, then usually myeloablative chemotherapy with peripheral blood stem cell rescue and radiation therapy to the primary site; there are also salvage chemotherapy regimens for residual disease after standard induction therapy or for relapsed NB; some examples of these chemotherapy combinations are: high-dose cyclophosphamide, topotecan and vincristine; high-dose cyclophosphamide, irinotecan and vincristine; irinotecan and temozolomide; or ifosfamide, carboplatin and etoposide
(Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Relapsed, refractory, or progressive disease, specifically: (a) Solid tumors: Following at least  prior systemic therapy, and no further standard therapy is available for the patient's advanced solid tumor at the time of enrollment; or (b) Classical HL: Following at least  prior systemic therapies in patients who are not candidates for autologous stem cell transplant (SCT), or following failure of autologous SCT; or (c) DLBCL: Following at least  prior systemic therapy; patients must have also received intensive salvage therapy unless they refused or were deemed ineligible; or (d) Indolent lymphoma: Following at least  prior chemoimmunotherapy regimen that included an anti-CD monoclonal antibody and for which no other more appropriate treatment option exists
Diagnosis of recurrent HL or NHL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory HL or NHL with a treatment plan that will include high dose therapy and stem cell transplantation
Patients should meet one of the following diagnosis:\r\n* Patients with primary progressive disease on induction therapy with new targeted therapies\r\n* Relapsed/refractory disease on new targeted therapies, i.e. thalidomide, lenalidomide, bortezomib, or other new novel agents such as carfilzomib, pomalidomide\r\n* Patients with relapsed multiple myeloma following previous autologous stem cell transplant\r\n* Plasma cell leukemia at diagnosis\r\n* High-risk patients with presence of chromosome p deletion (> %) in the bone marrow by fluorescence in situ hybridization (FISH); patients are not required to have prior autologous stem cell transplant
During phase II: all patients with relapsed disease will be eligible if they have received a minimum of  prior standard therapy and a maximum of  prior treatments (one of which must be a purine analog and/or an alkylating agent) for B-CLL and have developed relapse disease\r\n* Note: patients who have refractory disease (defined as  progressive disease on last treatment, or less than  months of clinical response to the last treatment) will not be eligible
High risk disease including at least one of the following:\r\n* Relapsed or refractory disease\r\n* Transformed lymphoma\r\n* Aggressive T-cell lymphoma\r\n* Failure to achieve completed remission (CR) following Auto SCT\r\n* Less than a % chance of event-free survival from autologous transplant determined by the treating physician and the Principal Investigator
Patients with relapsed disease are eligible if they have had no more than one prior therapy
Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that lasted >  months; refractory is no response or relapse within  months; previous biopsies <  months prior to treatment on this protocol will be acceptable\r\n* NOTE: Arms A/B  relapsed or refractory DLBCL within  months from the end of anthracycline-based therapy; no prior salvage therapy; patients can have received radiation therapy as part of initial treatment but not specifically for relapse\r\n* NOTE: Arm C patients include relapsed lymphoma patients of any type, other than those eligible for Arms A/B, for which the recommended treatment includes one of the platinum-based regimens; of note, relapsed double-hit high grade lymphoma patients and relapsed Hodgkin lymphoma patients will be enrolled in Arm C; there is no limit on the number of prior therapies for Arm C patients; the patient must be eligible for a platinum-based regimen and must not have received the same regimen in the past without responding
Patients with relapsed/refractory, biopsy-proven primary cutaneous T-cell lymphoma who have received at least two previous standard systemic therapies and, if MF/SS, is stage IB IVB at study entry.
ESCLATION COHORT: Patients must have a diagnosis of newly diagnosed and/ or relapsed/refractory AML with any of the following:\r\n* Confirmed translocation involving q\r\n* Partial tandem duplication(PTD) of the MLL gene (on q)\r\n* FLT-ITD (internal tandem duplication)\r\n* Increased Fgf in serum ( standard deviations above control serum samples)\r\n* HOX(A/A) over-expression in bone marrow (  standard deviations above control values in CD+ cells from normal subjects)\r\n* Note: Relapsed or refractory AML is defined as either: \r\n** Recurrence of disease after a complete remission (CR), or \r\n** Failure to achieve CR with initial therapy
Patients with T cell and natural killer (NK) cell lymphomas must be refractory to, be intolerant of, have relapsed following, or have refused all standard life-prolonging therapies
Subjects with myeloma that is relapsed and/or refractory to KRd when used in combination defined as progression of disease while on therapy or within  days of completing therapy
Diagnosis of relapsed or refractory AML and not candidate for standard consolidation treatment after daunorubicin and cytosine arabinoside OR diagnosis of APL relapsed after tretinoin (ATRA) and arsenic trioxide therapy or APL with persisting or rising blasts, and no other comparable or satisfactory alternative therapy available (including patients not eligible for, or who have access to, investigational therapies via a clinical trial)
Disease must be refractory or relapsed after >=  prior regimens (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)
Participant has a hematologic malignancy that is positive for MLLr as determined by fluorescent in situ hybridization (FISH) or reverse transcriptase (RT)-PCR, and disease meets at least one of the following criteria:\r\n* Relapsed after or is refractory to chemotherapy\r\n* Relapsed after hematopoietic stem cell transplantation (HSCT)\r\n* Relapsed or refractory secondary leukemia\r\n** Relapse is defined as reappearance of leukemia cells after the attainment of complete remission and refractory is defined as >= % blasts at the end of induction; patients that achieved MRD negative status followed by reappearance of blasts at less than % are eligible
The subject's disease is refractory or has relapsed following adequate BCG treatment. Refractory disease is defined as disease which persists at the first evaluation following adequate BCG. Relapsed disease is defined as having a complete response to adequate BCG but recurs at a subsequent evaluation. Subjects will enroll into one of three cohorts based on their type of disease and the time to refractory/relapsed disease following their last dose of BCG as follows:
Cohort : Subjects with CIS with or without associated papillary disease whose disease is determined to be refractory or relapsed within  months of the last dose of adequate BCG treatment.
Cohort : Subjects with CIS with or without associated papillary disease whose disease is determined to be refractory or relapsed more than  months but within  months of the last dose of adequate BCG treatment.
Histologically confirmed DLBCL at last relapse(by central pathology review before enrolment. .- Relapsed or refractory disease after ? lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
Inclusion Criteria:\n\n        Phase  Specific Patient at least yrs of age with histologically confirmed CLL/SLL or\n        B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma).\n\n        Phase a Inclusion\n\n          -  Histological evidence: FL Grade -A/iNHL, with relapsed or refractory disease (iNHL\n             includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade B, MCL, and transformed NHL\n             with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or\n             refractory.\n\n          -  Received BCR and/or BCL inhibitors were intolerant or had relapsed/refractory disease\n             afterwards.\n\n          -  Prior treatment for lymphoid malignancy for progressive /refractory disease\n\n          -  ?  prior regimen (min  cycles) with antibody conjugate, cytotoxic chemotherapy, or\n             TKI alone or in combination.\n\n          -  Measureable disease defined as: ?  lesion ? . cm single dimension via CT, CT/PET\n             with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenstrm's\n             macroglobulinemia presence of IgM l > X ULN; For CTCL: mSWAT > \n\n          -  Ability to provide diagnostic reports\n\n        General Inclusion\n\n          -  ECOG Score of  or .\n\n          -  Hematologic ANC > /uL and platelet > ,/uL,\n\n          -  Serum creatinine of < . ULN or calculated CrCl of >  mL/min\n\n          -  Bilirubin < .mg/dL (if Gilberts then < . mg/dL) and AST/AST < . ULN\n\n        Exclusion Criteria:\n\n          -  Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL\n             from Follicular NHL are eligible).\n\n          -  Prior transplant with stem cell infusion  days or active graft-versus-host treatment\n             within  weeks of Day .\n\n          -  Prior therapy with SYK inhibitors.\n\n          -  Chronic treatment with strong CYPA inhibitor/ inducer, acid reducing agent, Proton\n             pump inhibitors\n\n          -  Known lymphomatous involvement of the CNS.\n\n          -  Persistent, unresolved NCI CTCAE v. ? Grade , previous drug-related toxicity\n             (except alopecia, erectile impotence, hot flashes, libido, neuropathy).\n\n          -  Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate,\n             phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or\n             any test agent within  weeks or for alemtuzumab  weeks of Day .\n\n          -  For CTCL: (TSEBT) within  weeks, or initiation of topical steroid, nitrogen mustard,\n             or topical retinoid within  weeks. (Stable topical ?  weeks prior to Day  allowed).\n\n          -  Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be\n             HBsAg- or undetectable DNA\n\n          -  Active infection requiring systemic treatment,\n\n          -  Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or\n             malabsorption syndrome.\n\n          -  Major surgery within  weeks\n\n          -  Previous malignancies within  yrs. unless relapse risk is small (< %).\n\n          -  Current use of systemic steroids > mg QD prednisone (or equivalent)\n\n          -  Breastfeeding or pregnant (intention to become) females or participation in other\n             clinical trials
Histologically documented, CD-positive, relapsed or refractory (defined as having relapsed within  months to the previous treatment) FL or DLBCL (including primary mediastinal large B-cell lymphoma [PMLBCL])
Relapsed or refractory DLBCL, which has been histologically documented, defined as having received at least  but no more than  prior treatment regimens and ineligible for high-dose chemotherapy supported by autologous stem cell transplant.
Relapsed or refractory de novo or transformed DLBCL disease following at least one prior systemic therapy (for DLBCL)
Patients with histologically confirmed aggressive hematologic malignancies with chemotherapy-refractory disease; chemotherapy refractory disease is defined as one or more of the following: stable disease or progressive disease as best response to most recent chemotherapy containing regimen or disease progression or recurrence within  months of prior autologous or allogeneic stem cell transplant; subjects must have received adequate prior therapy including at a minimum: anti-cluster of differentiation (CD) monoclonal antibody unless tumor is CD-negative, an anthracycline containing chemotherapy regimen; subjects with transformed follicular lymphoma (FL) must have received prior chemotherapy for follicular lymphoma and subsequently have chemo-refractory disease after transformation to diffuse large B-cell lymphoma (DLBCL)
Patients must have received frontline therapy (including surgery, chemotherapy, autologous stem cell transplant [SCT] +/- MIBG, immunotherapy, radiotherapy, and retinoids) but may NOT have received second line chemotherapy for resistant/refractory, relapsed disease or progressive disease
Refractory disease (defined as persistence of evaluable disease after therapy) or relapsed disease following at least one prior treatment regimen that should include autologous stem cell transplant unless a patient was not eligible or refused prior transplant
Relapsed or refractory DLBCL, defined as having received at least  but no more than  prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant.
Histologically confirmed AML (defined using World Health Organization [WHO] criteria) with one of the following:\r\n* Primary refractory disease following =<  cycles of induction chemotherapy, or\r\n* First relapse with no prior unsuccessful salvage chemotherapy, or\r\n* Relapsed or refractory to hypomethylating agent, defined as a lack of response, disease progression, loss of response, or intolerance as deemed by the study investigator
Cohort B-: ) B- cell follicular lymphoma Grade , , or a (WHO criteria) ) Relapsed/refractory disease >=  lines separated by Progression, prior treatment (or not eligible for receiving) CD antibody ) Measurable disease (IWG -Lugano )
Only patients who received prior systemic therapy with relapsed/refractory organ disease are eligible, unless they have declined or are not eligible for high-dose melphalan and autologous hematopoietic stem cell transplant (HSCT) or any other standard therapy that has been known to be life-prolonging or life-saving
Patient has relapsed or relapsed/refractory multiple myeloma (MM);\r\n* Relapsed is defined as the development of disease progression following the achievement of stable disease (SD) or better to the most recent anti-MM regimen\r\n* Refractory is defined as experiencing less than a partial response (PR) to or progressive disease (PD) within  months after completion of the most recent anti-MM regimen
Multiple myeloma that is primary refractory or relapsed and refractory after at least  lines of standard for multiple myeloma including: a. >  consecutive cycles of both bortezomib and lenalidomide or thalidomide (alone or in combination) i. Patients who received bortezomib as their last therapy who were not refractory but developed bortezomib intolerance, as defined by the development of Grade  peripheral neuropathy with pain or > Grade  peripheral neuropathy after ?  consecutive cycles, are eligible b. Adequate alkylator therapy defined as: i. High-dose melphalan or other alkylating agent as conditioning for autologous or allogeneic stem cell transplant (SCT), or ii. ?  cycles of induction therapy, or iii. PD after ?  cycles
Patients must have relapsed or refractory disease following frontline chemotherapy; no upper limit for the number of prior therapies; patients may have relapsed after prior autologous or allogeneic stem cell transplant
Phase b: Participants with AML who are refractory to or have relapsed after initial treatment for their disease, with no more than three prior lines of therapy. Participants who have received prior treatment with cytarabine or decitabine are not excluded.
Patients must have either () refractory or relapsed high-risk NB (including n-myc proto-oncogene [MYCN]-amplified stage ///S of any age and MYCN-non amplified stage  in patients greater than  months of age) resistant to standard therapy, or () refractory or relapsed GD-positive tumor after receiving available life-prolonging therapies
Relapsed or refractory after ?  prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within  months of the last course of a standard regimen). Patients must have received Rituximab and alkylating agents.
Patients with relapsed or refractory disease following stem cell transplantation are permitted
Histologically confirmed B-cell NHL (FL or DLBCL): Relapsed from or refractory to ?  prior regimen containing rituximab, either alone or in combination, and not be a candidate for hematopoietic SCT or BM transplant
Non-Hodgkin's lymphoma with chemoresponsive disease in any of the following categories: \r\n* High grade lymphomas who have failed to achieve a first CR or have relapsed following a st remission who are not candidates for autologous transplants or transplants requiring the use of calcineurin inhibitors\r\n* Any NHL with therapy responsive disease which is considered not curable outside the transplant setting and not eligible/appropriate for autologous transplant or a higher priority protocol
Subjects with histologically confirmed relapsed or treatment refractory AML with the exception of subjects who are in first relapse following a remission > months in duration and are eligible for standard therapies (e.g., chemotherapy or stem cell transplantation).
For Pre-allo Part A (before stem cell transplant): Relapsed or refractory AML (greater than % blasts)
In addition to inclusion criteria listed for Part , Part  will enroll GCB-DLBCL tFL and MM subjects only. Relapsed and/or refractory MM or tFL that have failed prior standard therapy and for which there is no standard salvage regimen
have one of the following disease states: Acute Myeloid Leukemia (AML) (age < years) with relapsed/refractory disease; Chronic Lymphocytic Leukemia (CLL) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen
Patients must have progressive, relapsed or refractory disease after:\r\n* At least one prior systemic anti-lymphoma regimen (chemotherapy or immunotherapy except for transformed mycosis fungoides as described previously)\r\n* Relapsed or failed autologous or allogeneic stem cell transplant
Biopsy-confirmed relapsed, refractory, or progressive NHL or HL, including cutaneous T-cell lymphoma (CTCL)
Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least  prior rituximab containing chemotherapy regimen but no more than  prior lines of therapy
Must meet the criteria for relapsed and/or refractory disease according to the IWCLL guidelines (Hallek, ) to ?  prior treatment (with the exception of Arm B) and have evidence of disease progression requiring treatment at the time of study entry as follows: a. For Arms A and C, subjects must have received either prior chemoimmunotherapy or therapy with an approved BTK inhibitor with the following exceptions: i. Chemoimmunotherapy is not required if subjects have specific comorbidities that preclude the use of standard chemoimmunotherapy meeting at least  of the following criteria;
Refractory post-ASCT i. Disease progression or relapsed less than or equal to  months of ASCT (must have biopsy proven recurrence in relapsed subjects) ii. If salvage therapy is given post-ASCT, the subject must have had no response to or relapsed after the last line of therapy
Relapsed or refractory refers to patients who have received at least  prior treatment regimen for lymphoma (which may include prior autologous stem cell transplantation) and have demonstrated evidence of progressive disease by clinical and/or radiographic characteristics
Diagnosis of AML or ALL, relapsed or refractory after at least  prior treatment regimen. Newly-diagnosed patients ?  years old who have refused or are considered unfit for standard chemotherapy regimens or stem cell transplantation are also eligible.
Participants disease has relapsed after, is refractory to induction and/or salvage therapy, or has relapsed after hematopoietic stem cell transplant (HSCT)
Patients may not have received any anti-cancer therapy for their primary relapsed (rel)/refractory (ref) DLBCL with the exception of palliative radiation therapy (RT)
Participants must have relapsed or progressed after at least  prior course of anti-lymphoma therapy
Relapsed, refractory, or progressive disease following at least  prior systemic therapy. Patients with DLBCL or follicular lymphoma Grade  must have also received intensive salvage therapy.
Clinical diagnosis of relapsed/refractory B-cell Malignancies (B-Non-Hodgkins Lymphoma (NHL)) per International Workshop Group (IWG)
Subjects must have received >=  prior regimens for relapsed disease; induction therapy and stem cell transplant will be considered as one regimen
Patient has relapsed or relapsed/refractory multiple myeloma (MM)\r\n* Relapsed is defined as the development of disease progression following the achievement of stable disease (SD) or better to the most recent anti-MM regimen\r\n* Refractory is defined as experiencing less than a partial response (PR) to or progressive disease (PD) within  months after completion of the most recent anti-MM regimen
Arm A: Patients with AML who are  years of age or older with refractory or relapsed disease, or who have not received prior therapy but are not eligible to receive intensive frontline chemotherapy (i.e., Acute Group patients);
Subjects must have a pathologically documented, definitively diagnosed, clear cell RCC that is relapsed/refractory following at least two lines of systemic therapy (one of which must be a tyrosine kinase), or the subject refuses standard therapy
Participants diagnosed with any relapsed or refractory CD+ hematologic malignancy (e.g., primary mediastinal B-cell lymphoma) may be included in phase  of the study
Relapsed disease after standard st line therapy for aggressive lymphoma - not eligible for high dose chemotherapy with stem cell support. Relapsed or refractory disease after two lines of therapy one of which could have included Autologous Stem Cell Transplant (ASCT). Relapsed disease is defined as progression after a disease free interval of at least  months after completion of last therapy. Refractory is defined as progression of disease during prior therapy or within  months from its completion.
Relapsed is defined as experiencing PD that requires therapy but which is not refractory following the achievement of stable disease (SD) or better to the most recent anti-MM regimen.
Patients <  years of age with histologically confirmed refractory or relapsed Hodgkins disease (including patients who fail or relapse after autologous stem cell transplant [SCT]); this upper age limit will apply to transplants from both matched related and unrelated donors
Relapsed or refractory to greater than or equal to (>=)  prior lines of chemotherapy based on standard of care with certain requirements for prior therapy.
Phase II: Participants must have a diagnosis of AML and must have disease that has relapsed or is refractory to chemotherapy, or that has relapsed after hematopoietic stem cell transplantation (HSCT)\r\n* Refractory disease is defined as persistent disease after at least two courses of induction chemotherapy\r\n* Patients are eligible at first or subsequent relapse or any relapse that is refractory to salvage chemotherapy
Inclusion Criteria MEI- Alone:\n\n          -  Diagnosis of relapsed/refractory CLL and/or relapsed/refractory SLL or FL\n\n          -  No prior therapy with PIKd inhibitors\n\n          -  No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was\n             intolerant of BTK therapy\n\n          -  Subject must have failed at least  prior systemic therapy\n\n          -  QT-interval corrected according to Fridericia's formula (QTcF) ?  milliseconds (ms)\n\n          -  Left ventricular ejection fraction >%\n\n          -  For subjects, except those with CLL, must have at least one bi-dimensionally\n             measurable nodal lesion >. cm, as defined by Lugano Classification\n\n          -  Willingness to participate in collection of pharmacokinetic samples\n\n          -  A negative serum pregnancy test within  days of study Day , for females of\n             childbearing potential\n\n        Inclusion Criteria ME- in Combination with Rituximab\n\n          -  Diagnosis of relapsed/refractory CLL SLL or FL, MZL, DLBCL and high-grade B-cell\n             lymphoma. Subjects must meet the following criteria for relapsed or refractory\n             disease:\n\n               . Relapsed disease: a subject who previously achieved a CR or PR, but demonstrated\n                  disease progression after a response duration of > months\n\n               . Refractory disease: a subject who demonstrated disease progression within \n                  months of most recent therapy\n\n          -  No prior therapy with PIK? inhibitors\n\n          -  No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was\n             intolerant of BTK therapy\n\n          -  Subjects with CLL, SLL, FL, and MZL must have a failure of at least  prior systemic\n             therapy and be considered by the investigator a candidate for therapy with a\n             rituximab-based regimen; subjects with DLBCL and high-grade B-cell lymphoma must have\n             a failure of at least  prior therapies.\n\n          -  QT-interval corrected according to Fridericia's formula (QTcF) ? milliseconds (ms)\n\n          -  Left ventricular ejection fraction >%\n\n          -  For subjects, except those with CLL, must have at least one bi-dimensionally\n             measurable nodal lesion >. cm, as defined by Lugano Classification\n\n          -  Willingness to participate in collection of pharmacokinetic samples\n\n          -  A negative serum pregnancy test within  days of study Day  for females of\n             childbearing potential\n\n        Exclusion Criteria:\n\n          -  Known histological transformation from CLL to an aggressive lymphoma\n\n          -  Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia\n\n          -  Subjects who have tested positive for hepatitis B surface antigen and/or hepatitis B\n             core antibody\n\n          -  Positive for hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV)\n             antibody\n\n          -  Ongoing drug-induced pneumonitis\n\n          -  History of clinically significant cardiovascular abnormalities
Subjects disease must have relapsed or be refractory to at least  prior lines of therapy. Previous therapy must have included a CD-targeted agent and an anthracycline.
Patients with solid tumors with diagnoses OTHER than neuroblastoma or those listed above will be eligible if they meet both of the following criteria:\r\n* Immunohistochemical demonstration of GD expression on cell surface (tumor assessment by immunohistochemistry is required for this group of patients)\r\n* Have refractory or relapsed disease or metastatic disease
Subjects enrolled on the University of Pennsylvania/Abramson Cancer Center (UPCC)  CART- autologous T-cell trial with relapsed or refractory DLBCL and FL
More than  prior treatment regimens for the platinum-resistant/refractory relapsed EOC, FTC, or PTC, defined as investigational, chemotherapy, hormonal, biologic, or targeted therapy.